PHIBRO ANIMAL HEALTH CORP (PAHC)
PHIBRO ANIMAL HEALTH CORP (PAHC) from its SEC filings: 2026 revenue $1.5 billion (+17% vs the year before), net margin 7%, free cash flow $69.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2026) | $1.5 billion |
| Revenue growth | +17% |
| Net income | $99.7 million |
| Net margin | 6.6% |
| Free cash flow | $69.0 million |
| Diluted EPS | $2.43 |
| Latest quarter (Q1 2026 (calendar)) revenue vs a year earlier | +10% |
| Cash | $61.4 million |
| Long-term debt | $597.7 million |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.